rAAV Production Full Service, Large Scale
Features:
- Nonpathogenic with least immune response and best suitable for in vivo application.
- Excellent gene delivery efficiency in most cell types including dividing and non-dividing or primary cells.
- Multiple serotypes (AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-8, AAV-9, AAV-DJ/8 and AAV-DJ).
- Persistent transgene expression.
Large AAV cis vector inventory for constructing AAV cis plasmid with a specific promoter and reporter:
|
Single promoter rAAV cis vector
|
Dual promoter rAAV cis vector
|
|
Promoterless
CMV
CAG
H1
U6
Synapsin
UBC
EF1α
CBh
TRE-miniCMV
CMVtight
ALB(1.4)
MHCK7
ApoE/AAT1
CaMKII
ELA1
Enh358MCK
cTNT
GFAP
MBP
SST
TBG
αMHC
hRPE
mIP1
tMCK
|
|
Promoterless
CMV
CAG
H1
U6
Synapsin
UBC
EF1α
CBh
TRE-miniCMV
CMVtight
ALB(1.4)
MHCK7
ApoE/AAT1
CaMKII
ELA1
Enh358MCK
cTNT
GFAP
MBP
SST
TBG
αMHC
hRPE
mIP1
tMCK
|
CMV
CAG
H1
U6
Synapsin
UBC
EF1α
CaMKII
cTNT
GFAP
TRE-miniCMV
CMVtight
MHCK7
|
eGFP
RFP
mRFP
mCherry
tdTOMATO
TurboGFP
eYFP
Venus
Luc
LacZ
TRE-miniCMV
CMVtight
MHCK7
|
Service Description:
- Cloning your gene of interest (GOI) into AAV cis vector.
- rAAV cis plasmid large prep.
- rAAV packaging in 2xcell stack.
- rAAV purification via advanced 2xCsCl ultra-centrifugation.
- Desalting, filter sterilization and AAV titration via qPCR.
rAAV Serotypes We Offer:
AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-PHP.B, AAV-PHP.eB, AAV-PHP.S, AAV-DJ/8
and AAV-DJ.
Required Materials: A NCBI accession # or gene symbol or plasmid DNA carrying your gene of interest (GOI).
Turnaround Time: ~3 weeks.
Deliverables: >1.0 mL (10x0.1 mL) of super purified in vivo grade rAAV vector at >1E+13 VG/mL*.
We offer discount for new customer, please request a quote with us today.
Service Inquiry / Request a Quote
Super High Yield:
With our proprietary genetically engineered AAV·HT™ packaging cell and a advanced purification approach, the rAAV yield is easy to reach super high level--------total 1E+15 VG. For super high level rAAV production up to 1E+15 VG total, please contact us to request a quote.
Figure 1. A comparison of purity and infectivity of rAAV vectors from different sources showing super purified and super infectious (close to clinical trial grade) rAAV vector prepared via our advanced double CsCl ultra-centrifugation approach.
A. rAAV vectors (total 1E+9 VG per lane) from different sources were resolved on SDS-PAGE followed by silver staining. Lane 1: GMP manufactured rAAV vector from CHOP; Lane 2: rAAV prepared via our advanced 2xCsCl ultra-centrifugation approach; Lane 3: rAAV from Vector Core of BCM; Lane 4: rAAV from our competitor "V"; Lane 5: rAAV from our competitor "C"; Lane 6: Protein marker.
B. Super infectious rAAV vector prepared via advanced double CsCl ultra-centrifugation. Left panel: rAAV2-CAG-GFP (total 5E+9 VG) from our competitor "V" injected to mouse eye; Right panel: rAAV2-CAG-GFP (total 5E+9 VG) purified via advanced 2xCsCl ultra-centrifugation injected to mouse eye.
Figure 2. A comparison of infectivity of rAAV vectors from different sources showing super purified rAAV prepared via advanced double CsCl ultra-centrifugation approach is super infectious.
rAAV1-GFP (total 2E+9 VG) from different sources were injected to mouse muscle tissue. The GFP fluorescence was visualized 3 weeks post injection. A. rAAV1-GFP from our competitor "V"; B. rAAV1-GFP from our pre-made rAAVs stock purified via advanced double CsCl ultra-centrifugation. C. Quantification data showed that our super purified rAAV (bar 2) is ~ 9 times more infectious than that (bar 1) prepared via conventional CsCl ultra-centrifugation.
* Final viral yield may depend on the nature of transgene.
